A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
Karen W.L. Yee,John M. Storring,Rena Buckstein,Richard A. Wells,Anargyros Xenocostas,Michael J. Kovacs,Kang Howson-Jan,Eunice S. Wang,Kristina Battista,Lisa Wang,Amit M. Oza,S. Percy Ivy,Andre C. Schuh +12 more
TL;DR: Myelodysplastic syndromes are a heterogeneous group of malignant clonal disorders characterized by ineffective hematopoiesis and risk of progression to acute myeloid leukemia (AML).
Journal ArticleDOI
2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)
Amit M. Oza,Frédéric Selle,Irina Davidenko,Jacob Korach,Cesar Mendiola,Peter Gocze,Patricia Pautier,E. Chmielowska,Aristotle Bamias,Andrea Decensi,Z. Zvirbule,Antonio González-Martín,Roberto Hegg,Florence Joly,Claudio Zamagni,Angiolo Gadducci,Regula Deurloo,C. Revil,S. Robb,Nicoletta Colombo +19 more
Journal ArticleDOI
878pdbeneficial effect of adjuvant chemotherapy and whole abdominal or pelvic radiotherapy (waprt) on progression free and overall survival following primary surgery in patients with ovarian clear cell carcinoma (occc)
David Shao Peng Tan,Tzyvia Rye,C. Barrie,Patricia Shaw,Anthony Fyles,Stephane Laframboise,Lisa Wang,Charlie Gourley,Amit M. Oza +8 more
TL;DR: The data suggests that a combined adjuvant strategy of chemotherapy and WAPRT is associated with significantly improved PFS and OS in the treatment of OCCC.
Journal ArticleDOI
Resisting RECIST-Uniformity Versus Clinical Validity.
Michelle K. Wilson,Michael Friedlander,Stephanie Lheureux,William Small,Andres Poveda,Eric Pujade-Lauraine,Katherine Karakasis,Monica Bacon,Valerie Bowering,Tanya P. Chawla,Amit M. Oza +10 more
TL;DR: Reconnaissance Evaluation Criteria in Solid Tumors is a key criterion for endpoint assessment in clinical trials with its value recognized by clinicians, however, this survey also highlights the practical limitations of RECIST.
Proceedings ArticleDOI
340 Performance characteristics of screening strategies to identify Lynch syndrome in women with non-serous and non-mucinous ovarian cancer
Shana J. Kim,Alicia A. Tone,Aaron Pollett,Matthew Cesari,Blaise A. Clarke,Lua Eiriksson,Tae L. Hart,Spring Holter,Alice Lytwyn,Manjula Maganti,Leslie Oldfield,Trevor J. Pugh,S. Gallinger,Marcus Q. Bernardini,Amit M. Oza,D Vicus,V Dube,Raymond H. Kim,Sarah E. Ferguson +18 more
TL;DR: In this paper, the authors compared the performance characteristics between immunohistochemistry (IHC) for mismatch repair (MMR) proteins, microsatellite instability (MSI) testing and family history.